P-Bio

P-Bio is a biotechnology company focused on the development of next-generation protein therapeutics for metabolic and inflammatory diseases. The company utilizes a proprietary protein engineering platform to optimize the pharmacological properties of biologics, including extended half-life and enhanced potency. Its lead programs target metabolic disorders such as nonalcoholic steatohepatitis (NASH) and obesity through engineered versions of fibroblast growth factor 21 (FGF21) and other metabolic hormones. P-Bio aims to address significant unmet needs in chronic disease management by creating more effective and patient-friendly injectable therapies.